Randomised controlled trial of Amalaki Eye drop in comparison with Olopatadine 0.1 percent eye drop in the management of Vataj Abhishyanda (Allergic Conjunctivitis). - Nil

Start Date01 Nov 2024

Sponsor / Collaborator-

IRCT20240614062122N1 / RecruitingPhase 2IIT

Comparison effect of Olopatadine %0.2 cream with Fluocinolone %0.025 cream in the treatment of hand eczema in patients

Start Date06 Jul 2024

Sponsor / Collaborator-

IRCT20150426021944N5 / RecruitingPhase 3IIT

Comparing the efficacy of a combination of Mometasone and Olopatadine sprays versus Mometasone spray in children with allergic rhinitis

Start Date19 Jun 2024

Sponsor / Collaborator-

100 Clinical Results associated with Olopatadine Hydrochloride

100 Translational Medicine associated with Olopatadine Hydrochloride

100 Patents (Medical) associated with Olopatadine Hydrochloride

395

Literatures (Medical) associated with Olopatadine Hydrochloride

01 Sep 2024·Veterinary Ophthalmology

Efficacy of the topical antihistamine olopatadine in dogs with experimentally induced allergic conjunctivitis

Article

Author: Mamo, Esther T. ; Moorehead, Shelby C. ; Newbold, Georgina M.

AbstractObjectiveThe objective of the study was to evaluate the efficacy of a once a day, over the counter antihistamine eye drop, 0.7% olopatadine hydrochloride, in treating or preventing experimentally induced allergic conjunctivitis in dogs.Animals studiedTwelve systemically healthy pet dogs with no known history of allergies or atopic dermatitis, and in the past 12 months had no known ocular abnormalities.ProceduresDogs were randomly assigned to two groups: “Treatment” which received topical 0.7% olopatadine hydrochloride and “Control” which received artificial tears. Dogs received the antihistamine eye drops before (Phase 1) or after (Phase 2) receiving a compounded ophthalmic histamine solution to induce clinical signs of allergic conjunctivitis. Conjunctival hyperemia, chemosis, follicles, ocular discharge, and ocular pruritus were graded, and photographs were used to document changes. Schirmer tear test values, fluorescein staining, and intraocular pressures were monitored throughout.ResultsIn both Phase 1 and Phase 2, conjunctival scores increased 10 min after histamine administration (p < .05). There was no difference between maximum overall conjunctival scores between treatment and control groups in either phase or when comparing treatment groups of Phase 1 to Phase 2 (p > .05). However, treatment groups in Phase 2 did have a higher maximum conjunctival chemosis score and spent more time at their maximum chemosis score when compared to Phase 1 (p < .05).ConclusionOlopatadine may be beneficial as prophylaxis to reduce the degree and duration of clinical signs of allergic conjunctivitis.

01 Aug 2024·Hospital Pharmacy

Cost-effectiveness Analysis of Second-Generation Antihistamine 1 Receptor Blockers and Japanese Kampo Shoseiryuto for Treating Perennial Allergic Rhinitis in Outpatient Settings in Japan

Article

Author: Kashiwabara, Masami ; Egawa, Kei ; Nakagawa, Naoto ; Sasaki, Ayaka

Objectives: Perennial allergic rhinitis (PAR) is common in Japan. Second-generation antihistamines (SGAs) are commonly used for its treatment; however, it remains unclear which SGA is the most cost-effective. Additionally, the pharmacoeconomics of Japanese Kampo shoseiryuto (which was traditionally prescribed to treat PAR in Japan) remains poorly understood. In this study, we aimed to investigate the effectiveness of various SGAs and shoseiryuto for the treatment of PAR in Japanese outpatients, from the healthcare payer’s perspective. Methods: The most cost- and clinically effective SGAs were determined from a list of 6 SGAs (bepotastine, 10 mg; cetirizine, 10 mg; ebastine, 10 mg; epinastine, 20 mg; loratadine, 10 mg; and olopatadine, 5 mg) together with shoseiryuto, using the overall improvement rate through a model-based analysis. The time horizon was 28 days. Costs were determined based on the Medical Fee Index in 2020. Deterministic and probabilistic sensitivity analyses were conducted to address the uncertainty of the base-case results. Results: Overall, bepotastine (10 mg) and ebastine (10 mg) were cost-effective. Shoseiryuto was less cost-effective than ebastine (10 mg) (dominated). Ebastine (10 mg) was the most cost-effective option based on deterministic and probabilistic sensitivity analyses. Conclusions: Ebastine (10 mg) was the most cost-effective treatment strategy for PAR among the agents evaluated in this study. This insight could aid in establishing an appropriate formulary for treating PAR in hospitals and communities.

01 Jul 2024·Luminescence

Green and sensitive detection of olopatadine in aqueous humor using a signal‐on fluorimetric approach: GREEnness assessment

Article

Author: Noureldeen, Deena A. M. ; Omar, Mahmoud A. ; Mohamed, Abobakr A. ; Halawa, Mohamed Ibrahim ; Zeid, Abdallah M. ; Mostafa, Islam M.

AbstractOlopatadine (OLP) is widely utilized as an effective antihistaminic drug for alleviating ocular itching associated with allergic conjunctivitis. With its frequent usage in pharmacies, there arises a pressing need for a cost‐effective, easily implementable, environmentally sustainable detection method with high sensitivity. This study presents a novel signal‐on fluorimetric method for detecting OLP in both its pure form and aqueous humor. The proposed approach depends on enhancing the weak intrinsic fluorescence emission of OLP, achieving a remarkable increase of up to 680% compared to its intrinsic fluorescence. This enhancement is achieved by forming micelles around protonated OLP using an acetate buffer (pH 3.6) and incorporating a solution of sodium dodecyl sulfate (SDS) surfactant. A strong correlation (R = 0.9996) is observed between the concentration of OLP and fluorescence intensities ranging from 1.0 to 100.0 ng mL−1 with a limit of detection of 0.22 ng mL−1. This described method is successfully employed for quantifying OLP in both its powder form and pharmaceutical eye drops. Furthermore, it demonstrates robust performance in determining OLP in artificial aqueous humor with a percentage recovery of 99.05 ± 1.51, with minimal interference from matrix interferents. Moreover, the greenness of the described method was evaluated.

News (Medical) associated with Olopatadine Hydrochloride

01 Feb 2024

·www.biospace.com

Opthea Strengthens Team with Key Clinical and Regulatory Hires

Dr. Julie Clark, SVP Clinical Development; Dr. Fang Li, SVP Regulatory Affairs, to join February 1st Experienced executives bring extensive track record in products for retinal and ophthalmology diseases MELBOURNE, Australia, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT, “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced the appointment of Julie Clark, MD, MS, as Senior Vice President (SVP), Clinical Development, and Fang Li, Ph.D. RAC, as SVP, Regulatory Affairs, effective February 1, 2024. Dr. Clark and Dr. Li will report to Opthea Chief Executive Officer, Frederic Guerard, PharmD, MS, and will join the Opthea Executive Management Team. “It is my great pleasure to welcome two ophthalmology experts, Dr. Clark and Dr. Li, to the Company as we prepare for the next stage in our growth and work towards advancing the development of sozinibercept (OPT-302),” said Dr. Guerard. “Their past contributions to the development and registration of ophthalmology therapies such as IZERVAY™, BEOVU®, and EYLEA®, will be instrumental to the potential success of our lead program investigating sozinibercept, currently in two Phase 3 pivotal trials.” Dr. Clark shared, “I am thrilled to join Opthea as we prepare to complete patient enrollment in the pivotal Phase 3 clinical program for sozinibercept in the first half of 2024. The majority of my career has been dedicated to the clinical development of novel therapies for retinal diseases. Sozinibercept could be the first new drug for wet age-related macular degeneration (AMD) in more than 15 years, with the potential to deliver superior visual gains when administered in combination with standard of care therapy. I look forward to contributing to bringing this novel product candidate to patients with serious retinal disease.” Dr. Li commented, “As we work towards the potential release of topline results for our Phase 3 program in mid-2025, I am excited to apply my expertise to support the development and execution of our regulatory strategy and potential filings for sozinibercept in the U.S. and other markets. I look forward to the opportunity to bring Opthea’s innovative potential medicine through the regulatory process for the benefit of patients with retinal diseases.” Julie Clark, MD, MS With more than 15 years of experience in ophthalmology medical and clinical development, Dr. Clark brings expertise in both early and late-stage programs, regulatory submissions, and approvals. Her contributions include substantial support for the approval and launches of retinal therapies such as EYLEA®, JETREA® and BEOVU®. In Dr. Clark’s most recent position as Vice President Clinical Development at IVERIC bio, Inc., An Astellas Company, she oversaw the development program leading to the August 2023 U.S. Food and Drug Administration (FDA) approval of IZERVAY™, a complement inhibitor approved for the treatment of geographic atrophy secondary to age-related macular degeneration. Dr. Clark previously served as Chief Medical Officer at Adverum Biotechnologies Inc, where she played a crucial role in developing intravitreal delivered gene therapy for retinal diseases. Dr. Clark is a graduate of Wake Forest University and Wake Forest University School of Medicine in Winston-Salem, NC, U.S. Fang Li, PhD, RAC Dr. Li brings over 30 years of expertise in drug development and more than 20 years in regulatory affairs experience. Her experience spans various domains including small molecules, biologics, gene therapy, over-the-counter products, in-vitro diagnostic products and medical devices, with a specific focus on ophthalmology. She has held key roles at prominent ophthalmology companies such as Novartis AG, Alcon Inc., and Bausch + Lomb Corporation. Dr. Li's extensive background includes significant involvement in health authority interactions, U.S. FDA advisory committee meeting preparation and the establishment and leadership of regulatory teams. She has a proven track record of success in obtaining product approvals in the U.S. and other regions. Throughout her career, Dr. Li has played a pivotal role in leading numerous FDA drug approvals, specifically contributing to the approval of ophthalmology products like JETREA®, LOTEMAX® Ointment, SYSTANE® COMPLETE. She has also contributed to the development and registration of other ophthalmology drug products such as BEOVU®, PAZEO®, LOTEMAX® GEL, BESIVANCE®, and VYZULTA®. Fang holds a PhD in Medicinal Chemistry from China Pharmaceutical University, China. About Opthea Opthea Limited (ASX:OPT; NASDAQ:OPT, “Opthea”) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including neovascular (wet) age-related macular degeneration (wet AMD). Opthea’s lead product candidate sozinibercept is being evaluated in two pivotal Phase 3 clinical trials (ShORe, NCT04757610, and COAST, NCT04757636) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care. To learn more, visit and follow us on X and LinkedIn. Inherent risks of Investment in Biotechnology Companies There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialization and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. Companies such as Opthea are dependent on the success of their research and development projects and on the ability to attract funding to support these activities. Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore, investment in companies specializing in drug development must be regarded as highly speculative. Opthea strongly recommends that professional investment advice be sought prior to such investments. Forward-looking Statements This ASX announcement contains certain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. The words “expect”, “believe,” “should”, “could”, “may”, “will”, “plan” and other similar expressions are intended to identify forward-looking statements. Forward-looking statements in this ASX announcement include statements regarding expectations on the outcomes of Opthea’s Phase 3 clinical trials of sozinibercept, the potential for sozinibercept as a combination therapy to be the first therapy to achieve superior visual outcomes over anti-VEGF-A monotherapy and improve vision outcomes for patients with wet AMD, the expected timing for completion of enrollment for the Phase 3 studies and topline data, the market opportunity for sozinibercept, and the future performance of Opthea. Forward-looking statements, opinions and estimates provided in this ASX announcement are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current conditions. Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. They involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Opthea and its directors and management and may involve significant elements of subjective judgment and assumptions as to future events that may or may not be correct. These statements may be affected by a range of variables which could cause actual results or trends to differ materially, including but not limited to future capital requirements, the development, testing, production, marketing and sale of drug treatments, regulatory risk and potential loss of regulatory approvals, ongoing clinical studies to demonstrate sozinibercept safety, tolerability and therapeutic efficacy, additional analysis of data from Opthea’s Phase 3 clinical trials, timing of completion of Phase 3 clinical trial patient enrollment and clinical research organization and labor costs, intellectual property protections, and other factors that are of a general nature which may affect the future operating and financial performance of the Company including risk factors set forth in Opthea’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) on September 28, 2023 and other future filings with the SEC. Actual results, performance or achievement may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based. Subject to any continuing obligations under applicable law or any relevant ASX listing rules, Opthea disclaims any obligation or undertaking to provide any updates or revisions to any forward-looking statements in this ASX announcement to reflect any change in expectations in relation to any forward-looking statements or any change in events, conditions or circumstances on which any such statement is based, except as otherwise required by applicable law. Authorized for release to ASX by Frederic Guerard, CEO Company & Media Enquiries: Rudi Michelson Monsoon Communications Tel: +61 (0) 3 9620 3333 Investor Enquiries PJ Kelleher LifeSci Advisors Email: pkelleher@lifesciadvisors.com Join our email database to receive program updates: Tel: +61 (0) 3 9826 0399 Email: info@opthea.com Web:

Phase 3Executive ChangeDrug Approval

26 Oct 2023

·www.prnewswire.com

Nanoscope Therapeutics Strengthens Research and Development Leadership with Appointment of Najam Sharif, PhD, DSc.

DALLAS, Oct. 26, 2023 /PRNewswire/ -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, today announced the appointment of Najam Sharif, PhD, DSc, a veteran in drug/device discovery and development, as Vice President of Global Research and Development. "We are delighted to welcome Naj to the Nanoscope team," said Sulagna Bhattacharya, Co-Founder and Chief Executive Officer of Nanoscope. "His extensive experience in ophthalmology and pharmaceutical drug discovery and development is a natural fit for our organization, and we look forward to drawing on his clinical and regulatory expertise in particular at this pivotal time for MCO-010." "I am honored to join Nanoscope, a company that I see as transformative in the field of ophthalmology. As their lead asset, MCO-010, advances toward FDA approval, I look forward to the opportunity to positively impact the lives of people living with inherited retinal diseases, and to bring treatment options to a population for which there are no established cures," said Dr. Sharif. Dr. Naj Sharif brings over three decades of experience in pharmaceutical drug/device discovery and development to Nanoscope, including specialized expertise in ophthalmology and neuroscience. Throughout his career, he contributed to the discovery and development of several FDA-approved commercial drugs, including anti-glaucoma agent Travatan® and anti-allergic/inflammatory drugs such as Patanol® /Pataday® and Emedine®. In addition, Dr. Sharif was instrumental in guiding three drugs through to FDA approvals: Simbrinza® for glaucoma, IZBA® for the treatment of ocular hypertension and glaucoma, and PAZEO™ for the treatment ocular allergies. Most recently, Dr. Sharif served as Vice President, Global Biomedical Sciences & Head of Glaucoma and Neuroprotection at Santen, where he managed the company's Clinical Sciences, Data Sciences, and Biometrics departments, and where he also established and directed Global Alliances & External Research activities. Prior to this, he held positions related to R&D and regulatory affairs at Alcon Research-Novartis, Synaptic Pharmaceutical Corp, and Syntex Pharma / Roche Pharmaceutical Corp. He is widely published with an extensive number of peer-reviewed publications, edited books and holds multiple patents for mitigation of neurological and ophthalmic diseases. He has been an invited organizer, chairman and speaker at multiple national and international conferences. In addition to his professional experience, Dr. Sharif has served on numerous boards and committees. Dr. Sharif is an elected Fellow of multiple learned societies such as Association for Research in Vision and Ophthalmology, Association for Ocular Pharmacology and Therapeutics and British Pharmacological Society. Currently he serves on the Scientific Advisory Board of the Glaucoma Foundation and as an adjunct professor for the Duke-NUS Medical School in Singapore, and Institute of Ophthalmology at University College London. He is the recipient of several honors, including the Ernst H. Barany prize for "Outstanding Contributions to Ocular Pharmacology", the first and inaugural "Dr. Roger Vogel Award" for Pharmaceutical Research, and the Sir James Black Award for "Contributions to Drug Discovery". Dr. Sharif received a PhD in neuroscience, DSc (by thesis) in ophthalmology, and dual bachelor's degree in physiology and biochemistry from the University of Southampton (UK). About Nanoscope Therapeutics Inc. Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases, for which no cure exists. The company's lead asset, MCO-010, recently reported topline results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also recently completed their end-of-study visit for the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA fast track designations and FDA orphan drug designations for both retinitis pigmentosa and Stargardt. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophy. Investor Contact: Argot Partners 212-600-1902 [email protected] SOURCE Nanoscope Therapeutics

Phase 2Orphan DrugClinical ResultExecutive ChangeFast Track

11 May 2023

·www.drugs.com

The Most Common Allergy Medicines

THURSDAY, May 11, 2023 -- If you suffer from allergies, you know how bothersome and uncomfortable the sneezing and itchy eyes can be. These symptoms are more than irritating — they impact day-to-day activities like work, school, sports, sleeping and even eating. Not only that, but allergies can also cause more serious health problems such as asthma and even anaphylaxis, a life-threatening allergic reaction. Allergies are a common health condition affecting almost one-third of adults in the United States and just over one-quarter of children under 17, according to the U.S. Centers for Disease Control and Prevention . But there is relief at hand: Here’s what you need to know about the most common allergy medicines, the type of allergies they treat, how they work and common side effects. Antihistamines This type of allergy medicine is very effective in relieving allergy symptoms. Mayo Clinic explains this drug type works by blocking histamine, “a symptom-causing chemical released by your immune system during an allergic reaction.” Antihistamines are available as an over-the-counter medication or as a prescription allergy medicine, and they are sold in oral form, as a nasal spray or as eyedrops. This allergy medicine treats symptoms of indoor and seasonal allergies. Common side effects of antihistamines include drowsiness, dry mouth, dizziness, blurred or double vision, mucous thickening and low blood pressure. Common antihistamines include: Oral Loratadine (Alavert, Claritin) Cetirizine (Zyrtec) Diphenhydramine (Benadryl) Doxylamine (Vicks NyQuil, Tylenol Cold and Cough Nighttime) Fexofenadine (Allegra) Nasal spray Olopatadine (Patanase) Eyedrops Ketotifen (Zaditor) Leukotriene modifiers Leukotriene modifiers prevent or lessen the symptoms of allergic rhinitis (hay fever) and allergic asthma. The Cleveland Clinic explains that leukotrienes are chemicals released in the body when you come in contact with an allergen. This causes symptoms like a runny nose and coughing. Leukotriene inhibitors block the effects leukotrienes have on the body or “stop your body from producing them.” This allergy medicine treats symptoms of indoor and seasonal allergies. Leukotriene inhibitors can cause side effects such as cold or flu symptoms, headache, diarrhea, fatigue and itchy skin or rash. More serious side effects like depression, thoughts of suicide, hives, trouble breathing, vomiting and yellowing of the skin or eyes can occur. You should seek medical treatment in these cases. Common leukotriene inhibitors include: Montelukast (Singulair) Zafirlukast (Accolate) Zileuton (Zyflo) Corticosteroids Corticosteroids treat mild to severe allergy symptoms by reducing inflammation caused by your body’s reaction to an allergen. Corticosteroids are available in several forms including pills and liquids, nasal sprays, inhalers, creams and eyedrops. They treat allergic inflammation caused by indoor and seasonal allergens as well as insect stings. Severe allergic reactions are treated with oral corticosteroids, according to the Mayo Clinic. Side effects vary depending on the medication form, but can include increased blood glucose levels, high blood pressure, nosebleeds, mouth and throat irritation, and skin irritation. Common corticosteroids by form include: Pills and liquids Prednisolone (Prelone) Methylprednisolone (Medrol) Nasal sprays Budesonide (Rhinocort) Mometasone (Nasonex) Inhalers Fluticasone (Flovent) Mometasone (Asmanex Twisthaler) Creams Betamethasone (Dermabet, Diprolene) Desonide (Desonate, DesOwen) Eyedrops Fluorometholone (Flarex, FML) Loteprednol (Alrex, Lotemax) Immunotherapy Immunotherapy works by modifying the immune system and its reaction to allergens. It’s not used for immediate allergy symptom relief but is a long-term allergy treatment. Immunotherapy treatments (or allergy shots) are prescription medicines. "Allergy shots can be helpful for patients with seasonal and year-round allergies," Miranda Curtiss , an assistant professor at the University of Alabama at Birmingham School of Medicine, said in a recent article . "However, these are a long-term investment that require planning to continue therapy for three to five years for maximal benefit. Asthmatics who want to start allergy shots need to have their asthma under good control first before starting shots." With allergy shots, you are exposed to an allergen over and over until your immune system becomes desensitized and no longer reacts to the allergen, the Mayo Clinic says. This type of treatment is commonly given as allergy shots (subcutaneous immunotherapy, or SCIT), but is also available in a form given under the tongue (sublingual immunotherapy, or SLIT). With SCIT, injections are given in your doctor’s office where they can monitor for adverse reactions. Treatment starts with the “build-up phase,” which is once or twice a week, and decreases to a maintenance dose which is once every two to four weeks. Sublingual immunotherapy treatment, like subcutaneous immunotherapy, also exposes you to allergens over a period of time, with the goal of building immunity to the allergen. SLIT tablets are available by prescription and taken daily. Immunotherapy is used to treat seasonal and indoor allergies, as well as insect stings. Side effects include watery eyes, sneezing, mild asthma symptoms, a rash at the injection site, tiredness and headaches. In rare cases, life-threatening reactions such as throat swelling and difficulty breathing can occur. Regardless of the type of allergy or your symptoms, there are options for relief. Reach out to your health care provider to learn more about which remedies are best for you. Posted May 2023

Immunotherapy

100 Deals associated with Olopatadine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D01192	Olopatadine Hydrochloride	R01AC08 S01GX09	DB00768

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Allergic rhinoconjunctivitis	JP	Novartis Pharma KK	26 Jul 2006
Seasonal allergic conjunctivitis	NO	Novartis Europharm Ltd.	16 May 2002
Seasonal allergic conjunctivitis	LI	Novartis Europharm Ltd.	16 May 2002
Seasonal allergic conjunctivitis	IS	Novartis Europharm Ltd.	16 May 2002
Seasonal allergic conjunctivitis	EU	Novartis Europharm Ltd.	16 May 2002
Pruritus	JP	Kyowa Kirin Co., Ltd.	22 Dec 2000
Rhinitis, Allergic	JP	Kyowa Kirin Co., Ltd.	22 Dec 2000
Urticaria	JP	Kyowa Kirin Co., Ltd.	22 Dec 2000
Conjunctivitis, Allergic	US	Alcon Laboratories, Inc.	18 Dec 1996

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Urticaria	NDA/BLA	CN	Anhui Sihuan Kebao Pharmaceutical Co., Ltd.	30 Sep 2024
Acute conjunctivitis	Discovery	-	Alcon Research Ltd.	01 Oct 2009
Conjunctivitis, Allergic	Discovery	-	Alcon Research Ltd.	01 Oct 2009
Rhinitis, Allergic	Discovery	US	Alcon Research Ltd.	01 Oct 2008
Rhinitis, Allergic, Seasonal	Discovery	US	Novartis Pharmaceuticals Corp.	15 Apr 2008
Rhinitis, Allergic, Perennial	Discovery	US	Alcon Research Ltd.	01 Dec 2006
Rhinoconjunctivitis	Discovery	-	Alcon Research Ltd.	18 Apr 2006
Seasonal allergic conjunctivitis	Discovery	-	Alcon Research Ltd.	18 Apr 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02478398 (CTgov)	Phase 3	Rhinitis, Allergic, Seasonal \| Asthma \| Allergic rhinoconjunctivitis	1,025	Mometasone furoate monohydrate+Self-injectable epinephrine+Olopatadine+Albuterol+Loratadine+Short ragweed pollen allergen extract (Short Ragweed Pollen Allergen Extract)	nphdghhrmb(tzeirmpmcg) = gskafncczp wumsplfaer (wmwkvuktdd, galdzfknru - uqkznqsqlv) View more	-	09 Jul 2019
				Placebo+Mometasone furoate monohydrate+Self-injectable epinephrine+Olopatadine+Albuterol+Loratadine (Placebo)	nphdghhrmb(tzeirmpmcg) = pmuknrtjue wumsplfaer (wmwkvuktdd, dzblxwkbxs - xlelmcxrzv) View more
APAO2019	Not Applicable	Vernal Keratoconjunctivitis	96	Olopatadine 0.1%	(vrpndkjgin) = hjztblhuwe trcwentaav (tokfqyjhlt )	Positive	06 Mar 2019
				Sodium Cromoglycate 2%	(vrpndkjgin) = gfuibrhkty trcwentaav (tokfqyjhlt )
NCT00609128 (CTgov)	Not Applicable	Conjunctivitis, Allergic \| Lacerations	21	olopatadine	wigzakzrde(zvhxdhkjxi) = opbrfxkglx vwzcglrqyt (nnpebxkbsi, ojtazirpgy - smwvjzgymz) View more	-	20 Sep 2018
ARVO2016	Not Applicable	Anaphylaxis	111	Lastacaft	(phrpihmebn) = bouhecijui zwsvnujssb (bvfjpaluco )	-	01 May 2016
				Pataday	(phrpihmebn) = jctlpcqjor zwsvnujssb (bvfjpaluco )
NCT01363700 (CTgov)	Phase 3	Conjunctivitis, Allergic	87	Epinastine (DE-114) (Epinastine (DE-114) Ophthalmic Solution)	rsmhtqepym(xbfbkdbxtj) = frvepioxzj qudngacfki (qtzgfmzrof, zxqhecqaml - arwdkatpxu) View more	-	05 Nov 2014
				Placebo (Placebo Ophthalmic Solution)	rsmhtqepym(xbfbkdbxtj) = amhlnbgnsd qudngacfki (qtzgfmzrof, usepuwdksr - ogocusvieh) View more
NCT01470118 \| NCT01732757 (Pubmed \| Adv Ther)	Phase 4	Conjunctivitis, Allergic	284	Alcaftadine 0.25%	(sdeeuohnvh) = uoyyydoawc ubxxpxyakl (ojloptuuwm )	Positive	01 Oct 2014
				Olopatadine 0.2%	(sdeeuohnvh) = bilbmlvedb ubxxpxyakl (ojloptuuwm )
NCT01697969 (CTgov)	Phase 4	Conjunctivitis, Allergic	17	Olopatadine hydrochloride (Left Eye)	hkguwmganp(axuexssmbb) = doefomevgg qojzrtpzgj (iuyvtvlyiz, talctrvmyt - uwijbodwig) View more	-	18 Aug 2014
				Olopatadine hydrochloride (Right Eye)	hkguwmganp(axuexssmbb) = jyivhofqbh qojzrtpzgj (iuyvtvlyiz, awuoawiolq - eabnltlrwn) View more
NCT01743027 (CTgov)	Phase 3	Conjunctivitis, Allergic	902	AL-4943A ophthalmic solution (AL-4943A)	xcihfllbcs(mhstducteu) = sutkhoghrb vmtprxcohd (htiavddkzf, pndrusgnwl - bkkkwbwisc) View more	-	11 Aug 2014
				Olopatadine hydrochloride ophthalmic solution, 0.2% (PATADAY)	xcihfllbcs(mhstducteu) = umseyligkr vmtprxcohd (htiavddkzf, eoptgstujf - yxjvjlsvae) View more
NCT01698814 (CTgov)	Phase 3	Conjunctivitis, Allergic	518	AL-4943A Ophthalmic Solution (AL-4943A)	cqpkglnvhi(rwcdylbrxv) = uvgvgdwoqa sugjekxcbv (ubkcvwvipw, odtjecifzz - fbbhcbdwuc) View more	-	28 Feb 2014
				AL-4943A Ophthalmic Solution (AL-4943A Vehicle)	cqpkglnvhi(rwcdylbrxv) = fpqoobvkuu sugjekxcbv (ubkcvwvipw, fplwvivqli - xoelqgqhnw) View more
NCT01732757 (CTgov)	Phase 4	Acute conjunctivitis \| Conjunctivitis, Allergic	157	Alcaftadine 0.25% (Lastacaft®)	cxuquzjmww(dmczvpctzx) = bzqebrxriu szaqxftdho (nrreaftxoj, fblagyocsr - rwsxqhdmkl) View more	-	14 Jan 2014
				Olopatadine 0.2% (Pataday™)	cxuquzjmww(dmczvpctzx) = yrywuyujko szaqxftdho (nrreaftxoj, akgtqeklet - orfailzqpz) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis